Comments
Hyderabad, Feb 27 Granules India has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Losartan Potassium tablets.
It is bioequivalent to the reference listed drug product (RLD), Cozaar Tablets of Organon LLC. Losartan potassium tablets are indicated for the treatment of hypertension in adults and paediatric patients 6 years of age and older, to lower blood pressure.
The current annual US market for Losartan potassium tablets is approximately $336 million, according to a release. Granules now has a total of 54 ANDA approvals from USFDA (52 final approvals and two tentative approvals).
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.